• Journal of Endocrine Surgery
• /
• 제18권4호
• /
• pp.236-239
• /
• 2018

Secondary hyperparathyroidism (SHPTH) occurs commonly in patients with end-stage renal disease (ESRD). Uncontrolled SHPTH is associated with complications of calcium deposition including calciphylaxis and elevated rates of cardiovascular morbidity. Current treatment recommendations for medically refractory disease include total parathyroidectomy, often with autotransplantation (TPTH+AT) of minced parathyroid gland. Surgical intervention is associated with a reduction in cardiovascular mortality. We report a case of a 56-year-old man with ESRD who developed SHPTH and underwent TPTH+AT of parathyroid tissue into the right brachioradialis muscle. Over the course of 7 years he developed a mass at the site of the autotransplanted gland as well as recurrent refractory hyperparathyroidism with increased forearm uptake noted on sestamibi scan. After excision of this mass, pathology demonstrated hyperplasia of the minced gland fragments which were embedded within a mass of fibroadipose tissue rather than the muscle tissue it was originally transplanted in.

• 한국환경생물학회:학술대회논문집
• /
• 한국환경생물학회 2001년도 학술대회
• /
• pp.109-110
• /
• 2001

• 환경생물
• /
• 제21권2호
• /
• pp.158-163
• /
• 2003

유기주석화합물은 독성이 강하고 잔존력이 감하여 수계환경으로 유입되면 해양생태계에 오랫동안 영향을 미친다 이들 화합물이 해양생불에 미치는 영향에 관해서는 어류나 패류 등의 산업적 가치가 큰 생물종을 대상으로 한 연구는 적지 않지만, 해양생태계에서 먹이사슬의 가장 하부에 위치하며 기초생산을 담당하는 플랑크톤류에 미치는 영향에 관해서는 잘 알려져 있지 않다. 따라서 본 연구에서는 TBT류의 TBTC, TBTO, TBTA, TBTB를 비롯하여 TPT류의 TPTC, TPTF, TPTH가 기수산 rotifer의 생존에 미치는 독성(96 hr-LC$_{50}$)을 조사.비교하였다. 그 결과, TBT류에서는 TBTA(1.1 ppb)가 가장 강하였고 TBTC (2.0), TBTB (3.3), TBTO (5.6)의 순이었으며, TPT류에서는 TPTF (1.0), TPTC (1.1), TPTH(1.6)의 순이었다. 이 결과는 TPT류가 전반적으로 TBT류에 비해 독성이 강하다는 것을 보여준다.다.

• Korean Journal of Radiology
• /
• 제25권3호
• /
• pp.289-300
• /
• 2024

Objective: To prospectively evaluate the outcomes of ultrasound (US)-guided radiofrequency ablation (RFA) in tertiary hyperparathyroidism (THPT). Materials and Methods: Patients with THPT underwent RFA between September 2017 and January 2022. Laboratory parameters, including serum intact parathyroid hormone (iPTH) levels, were monitored for 48 months after RFA and compared with the levels at baseline. Complications related to RFA and changes in hyperparathyroidism-related clinical symptoms were recorded before and after RFA. Results: A total of 42 patients with THPT were recruited for this study. Ultimately, 36 patients with renal failure and 2 patients who underwent successful renal transplantation (male:female, 17:21; median age, 54.5 years) were enrolled. The follow-up time was 21.5 ± 19.0 months in the 36 patients with renal failure. In these 36 patients, iPTH levels were significantly decreased to 261.1 pg/mL at 48 months compared with the baseline value of 1284.9 pg/mL (P = 0.012). Persistent hyperparathyroidism, defined as iPTH levels maintained at > 585.0 pg/mL for 6 months after treatment, occurred in 4.0% of patients (1/25). Recurrent hyperparathyroidism, defined as iPTH levels > 585.0 pg/mL after 6 months, were 4.0% (1/25) and 0.0% (0/9) at 6 months and 4 years after treatment, respectively. In two patients with THPT after successful renal transplantation, iPTH decreased from the baseline value of 242.5 and 115.9 pg/mL to 171.0 and 62.0 pg/mL at 6 months after treatment. All complications resolved within 6 months of ablation without medical intervention, except in 10.5% (4/38) patients with permanent hypocalcemia. The overall symptom recovery rate was 58.8% (10/17). The severity scores for bone pain, arthralgia, and itchy skin associated with hyperparathyroidism improved after treatment (P < 0.05). Conclusion: US-guided RFA is an effective and safe alternative to surgery in the treatment of patients with TPTH and improves hyperparathyroidism-related clinical symptoms.